JULIEN MAZIERES

PROFESSOR

France

Research Interests

Explore related searches

Professors in France Professors in Immunology Immunology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (13)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (12)

Valerio Iebba

Assistant Professor

University of Trieste

ITALY

View details

Christophe Dooms

University Hospitals Leuven

BELGIUM

View details

laurence ZITVOGEL

Université Paris-Saclay

FRANCE

View details

Raimond Ravelli

Professor

University of Maastricht

NETHERLANDS

View details

Dariusz Kowalski

MD, PhD, Prof

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND

View details

Silvia NOVELLO

Professor

Università degli Studi di Torino

ITALY

View details

Safae TERRISSE

INSERM

FRANCE

View details

Antonio Peixoto

Scientific Head Of Imaging Core Facility

FRANCE

View details

Kristina Holmberg

Head of Clinical Biomarkers

Lund University

DENMARK

View details

Benjamin Solomon

Professor

University of Melbourne

AUSTRALIA

View details

ENRIQUETA FELIP

Head Thoracic Oncology Unit (After Competitive Exam)

Hospital Universitari Vall d'Hebron

SPAIN

View details

Christian Chalut

Institute of Pharmacology and Structural Biology

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

JULIEN MAZIERES

Research Interests

Explore related searches

Contact this professor

Articles (13)

Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

A pragmatic guide for management of adverse events associated with lorlatinib

Protein Kinase Inhibitors Indicated for Lung Cancer: Pharmacodynamics, Pharmacokinetics, Adverse Drug Reactions, and Evaluation in Clinical Trials

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase 2 NeoCOAST Platform Trial

MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial

INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

Mycobacteria–host interactions in human bronchiolar airway organoids

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel

Collaborators (12)

Valerio Iebba

Christophe Dooms

laurence ZITVOGEL

Raimond Ravelli

Dariusz Kowalski

Silvia NOVELLO

Safae TERRISSE

Antonio Peixoto

Kristina Holmberg

Benjamin Solomon

ENRIQUETA FELIP

Christian Chalut

Make your next move.